Healio – All News - Latest News and Information
SightGlass Vision’s DOT (Diffusion Optics Technology) lenses were shown in two 12‑month trials—North American CYPRESS and Chinese CATHAY—not to increase astigmatism in children compared with control spectacles. The studies also confirmed that DOT lenses slow axial length growth and spherical equivalent progression, with similar efficacy across both populations. The lenses achieve myopia control through contrast modulation rather than peripheral defocus, a mechanism that appears neutral to astigmatic development. Findings address clinician concerns about refractive side‑effects and support broader adoption of DOT technology.
The FDA has granted first‑line approval for a nivolumab‑plus‑AVD regimen in patients aged 12 and older with stage III‑IV classical Hodgkin lymphoma. The decision follows the phase 3 SWOG S1826 trial, which showed a 58% progression‑free survival rate and a hazard ratio of...
New Korean cohort study shows that cumulative exposure to elevated blood pressure between ages 30 and 40 markedly raises later‑life cardiovascular and kidney disease risk. Every 10 mm Hg increase in systolic pressure above 120 mm Hg was linked to a 27 % higher hazard...
A large Swedish cohort study published in Nature Medicine shows that antibiotics can disturb the gut microbiome for up to eight years, with the most pronounced changes occurring within the first year. The research, which analyzed fecal metagenomes of 14,979...
The U.S. District Court temporarily blocked the Trump administration’s effort to revise the CDC childhood immunization schedule, preserving universal hepatitis B birth‑dose and routine hepatitis A vaccinations. The American Association for the Study of Liver Diseases (AASLD) backed the ruling after months...
Patients with eczema continue to encounter significant insurance obstacles, according to a 2025 National Eczema Association (NEA) survey. The study found that 40% of respondents experienced coverage issues, 15% never began prescribed therapy, and step‑therapy and prior‑authorization requirements delayed treatment...
Dr. James R. Kelly reports that enhancement rates for presbyopia‑correcting intraocular lenses have dropped from double‑digit levels in the early 2000s to roughly 5% by 2020, thanks to advances in lens optics and surgical technique. Residual refractive error under 0.5...
Geographic atrophy (GA) management is poised to benefit from AI‑driven OCT analysis, which can quantify ellipsoid zone (EZ) loss, EZ‑RPE ratio, and EZ thickness with micron‑level precision. In Europe, imaging tools like the Topcon GA Monitor are approved, while the...
NovaBridge’s VIS‑101, a dual VEGF‑A and angiopoietin‑2 inhibitor, delivered rapid and durable efficacy in a phase 2a trial of 38 wet AMD patients in China. Participants receiving 3 mg or 6 mg doses achieved mean visual gains exceeding 10 ETDRS letters and central...
Qlaris Bio announced that Fred Guerard, PharmD, will serve as its president and chief executive officer, succeeding co‑founder Thurein Htoo. The biotech is moving its lead candidate, QLS‑111, into Phase 3 trials for open‑angle glaucoma and ocular hypertension. Guerard arrives with...
A retrospective TriNetX analysis of 1,691 psoriasis patients compared bimekizumab with IL‑23 inhibitors and found no greater incidence of new‑onset depression, suicidal ideation, or related medication use. Over a two‑year follow‑up, the combined psychiatric event rate was 4.9% for bimekizumab...
A randomized, double‑blind study published in Mayo Clinic Proceedings found that a single 25 mg dose of off‑prescription Adderall caused significant acute increases in blood pressure and heart rate among healthy young adults. Systolic pressure rose by roughly 10 mm Hg, diastolic by...
SpyGlass Pharma’s Bimatoprost Drug Pad‑IOL System demonstrated significant intra‑ocular pressure (IOP) reductions and vision gains in a phase 1/2 trial of 104 patients with open‑angle glaucoma or ocular hypertension undergoing cataract surgery. At 12 months, the 78 µg dose lowered mean IOP 34%...
The U.S. Food and Drug Administration has approved Novartis' secukinumab, marketed as Cosentyx, for adolescents aged 12 and older with moderate‑to‑severe hidradenitis suppurativa (HS). This marks the first IL‑17A inhibitor cleared for a pediatric indication, extending the drug’s adult HS...
Minnesota reported the largest U.S. outbreak of Trichophyton mentagrophytes genotype VII (TMVII), a sexually transmitted fungal infection that appears as round, red rashes and can be mistaken for eczema, psoriasis or bacterial skin conditions. More than 30 cases have been confirmed,...
